This combination is rational as ibrutinib blocks inducible T‐cell kinase in addition to BTK and with resultant enhanced Th1‐type cellular immunity [118]; ongoing TRANSCEND‐004 clinical trial is evaluating this combination in patients with CLL (NCT03331198). Here, BTK is linked to B-cell chronic lymphocytic leukemia.